复方青黛、ATRA与化疗交替治疗缓解后急性早幼粒细胞白血病  

Clinical effect of compound qingdai tablets,all-trans retinoic acid and chemotherapy for treatment of acute promyelocytic leukemia of complete remission

作　　者：时新颖[1] 潘登[1] 郑顶运[1] 黄明[1] 

机构地区：[1]安徽省阜阳市人民医院血液科,236000

出　　处：《蚌埠医学院学报》2005年第4期317-318,共2页Journal of Bengbu Medical College

摘　　要：目的:观察复方青黛片、全反式维A酸(alltransretinoicacid,ATRA)与化疗交替治疗缓解后急性早幼粒细胞白血病(acutepromyelocyticleukemia,APL)临床疗效。方法:对初诊24例APL患者,先用复方青黛片或ATRA治疗达完全缓解,再用化疗与ATRA、复方青黛片序贯交替治疗,持续缓解3年以上者监测PML/RARα基因,再决定是否停药或继续治疗。结果:24例全部存活,复发率8.3%,未发现严重副作用。结论:复方青黛片、ATRA与化疗交替治疗APL疗效满意,副作用少。Objective:To observe the clinical effect of compound qingdai tablets,all-trans retinoic acid(ATRA) and chemotherapy for the treatment of acute promyelocytic leukemia(APL) of complete remission.Methods:Twenty-four cases of newly diagnosed APL were induced to complete remission by using compound qingdai tablets or ATRA first,then treated alternatively with compound qingdai tablets,ATRA and chemotherapy.We monitored the PML/RARα fusion genes of the patients who maintained remission for 3 years and then decided whether to stop the therapy or continue.Results:All the cases survived.The relapse rate was 8.3% and the side effect was mild.Conclusions:The therapy of sequential use of compound qingdai tablets,ATRA and chemotherapy for treatment of APL of complete remission has the advantages of good results and mild side effects.

关 键 词：白血病 早幼粒细胞 急性 复方青黛片 全反式维A酸 肿瘤/药物疗法 

分 类 号：R733.71[医药卫生—肿瘤]